Vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating peptide receptor 2 deficiency in mice results in growth retardation and increased basal metabolic rate

Endocrinology

Volumn 143, Issue 10, 2002, Pages 3994-4006

  Asnicar, Mark A ^a   Köster, Anja ^b   Heiman, Mark L ^c   Tinsley, Frank ^d   Smith, Dennis P ^b   Galbreath, Elizabeth ^a   Niles, F O X ^b   Yanfei Linda, Ma ^c   Blum, Werner F ^d   Hsiung, Hansen M ^a,b  

^a Divisions of Endocrine Research   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c LILLY DEUTSCHLAND GMBH   (Germany)

^d UNIVERSITY HOSPITAL GIESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANIMAL TISSUE; ARTICLE; BASAL METABOLIC RATE; CALORIMETRY; CIRCADIAN RHYTHM; ENERGY EXPENDITURE; GROWTH RETARDATION; LIGHT DARK CYCLE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN FAMILY; RECEPTOR AFFINITY; RECEPTOR BINDING; RESPIRATORY QUOTIENT; SEMINIFEROUS TUBULE; SMOOTH MUSCLE FIBER;

AMINO ACID SEQUENCE; ANIMALS; BASAL METABOLISM; BODY COMPOSITION; FEMALE; GROWTH; GROWTH DISORDERS; INFERTILITY, MALE; INSULIN; INSULIN-LIKE GROWTH FACTOR I; LEPTIN; MALE; MICE; MICE, KNOCKOUT; MOLECULAR SEQUENCE DATA; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE, TYPE II; REFERENCE VALUES; SEMINIFEROUS TUBULES; SEX CHARACTERISTICS; SPERM COUNT;

EID: 0036772780     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/en.2002-220354     Document Type: Article

References (37)

1. Said SI, Mutt V 1969 Long acting vasodilator peptide from lung tissue. Nature 224:699-700
2. Said SI, Mutt V 1970 Polypeptide with broad biological activity: Isolation from small intestine. Science 169:1217-1218
3. Said SI 1991 Vasoactive intestinal peptide. Biologic role in health and disease. Trends Endocrinol Metab 2:107-112
4. Van Rampelbergh J, Poloczek P, Francoys I, Delporte C, Winand J, Robberecht P, Waelbroeck M 1997 The pituitary adenylate cyclase activating polypeptide (PACAP I) and VIP (PACAP II VIP1) receptors stimulate inositol phosphate synthesis in transfected CHO cells through interaction with different G proteins. Biochim Biophys Acta 1357:249-255
5. Ishihara T, Shigemoto R, Mori K, Takahashi K, Nagata S 1992 Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide. Neuron 8:811-819
6. Sreedharan SP, Huang JX, Cheung MC, Goetzl EJ 1995 Structure, expression, and chromosomal localization of the type I human vasoactive intestinal peptide receptor gene. Proc Natl Acad Sci USA 92:2939-2943
7. Sreedharan SP, Patel DR, Huang JX, Goetzl EJ 1993 Cloning and functional expression of a human neuroendocrine vasoactive intestinal peptide receptor. Biochem Biophys Res Commun 193:546-553
8. Harmar AJ, Arimura A, Gozes I, Journot L, Laburthe M, Pisegna JR, Rawlings SR, Robberecht P, Said SI, Sreedharan SP, Wank SA, Waschek JA 1998 International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev 50:265-270
9. Delgado M, Martinez C, Johnson MC, Gomariz RP, Ganea D 1996 Differential expression of vasoactive intestinal peptide receptors 1 and 2 (VIP-R1 and VIP-R2) mRNA in murine lymphocytes. J Neuroimmunol 68:27-38
10. Lutz EM, Sheward WJ, West KM, Morrow JA, Fink G, Harmar AJ 1993 The VIP2 receptor: Molecular characterisation of a cDNA encoding a novel receptor for vasoactive intestinal peptide. FEBS Lett 334:3-8
11. Hashimoto H, Ishihara T, Shigemoto R, Mori K, Nagata S 1993 Molecular cloning and tissue distribution of a receptor for pituitary adenylate cyclase-activating polypeptide. Neuron 11:333-342
12. Usdin TB, Bonner TI, Mezey E 1994 Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology 135:2662-2680
13. Sheward WJ, Lutz EM, Harmar AJ 1995 The distribution of vasoactive intestinal peptide2 receptor messenger RNA in the rat brain and pituitary gland as assessed by in situ hybridization. Neuroscience 67:409-418
14. Wei Y, Mojsov S 1996 Multiple human receptors for pituitary adenylyl cyclase-activating polypeptide and vasoactive intestinal peptide are expressed in a tissue-specific manner. Ann NY Acad Sci 805:624-627
15. Wei Y, Mojsov S 1996 Tissue specific expression of different human receptor types for pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide: Implications for their role in human physiology. J Neuroendocrinol 8:811-817
16. Wei Y, Mojsov S 1996 Distribution of GLP-1 and PACAP receptors in human tissues. Acta Physiol Scand 157:355-357
17. Delgado M, Leceta J, Abad C, Martinez C, Ganea D, Gomariz RP 1999 Shedding of membrane-bound CD14 from lipopolysaccharide-stimulated macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide. J Neuroimmunol 99:61-71
18. Adamou JE, Aiyar N, Van Horn S, Elshourbagy NA 1995 Cloning and functional characterization of the human vasoactive intestinal peptide (VIP)-2 receptor. Biochem Biophys Res Commun 209:385-392
19. Moller K, Sundler F 1996 Expression of pituitary adenylate cyclase activating peptide (PACAP) and PACAP type I receptors in the rat adrenal medulla. Regul Pept 63:129-139
20. Delgado M, Abad C, Martinez C, Leceta J, Gomariz RP 2001 Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med 7:563-568
21. Jamen F, Persson K, Bertrand G, Rodriguez-Henche N, Puech R, Bockaert J, Ahren B, Brabet P 2000 PAC1 receptor-deficient mice display impaired insulinotropic response to glucose and reduced glucose tolerance. J Clin Invest 105:1307-1315
22. Shen S, Spratt C, Sheward WJ, Kallo I, West K, Morrison CF, Coen CW, Marston HM, Harmar AJ 2000 Overexpression of the human VPAC2 receptor in the suprachiasmatic nucleus alters the circadian phenotype of mice. Proc Natl Acad Sci USA 97:11575-11580
23. Tinsley FC, Taicher GZ, Heiman ML 2001 Novel NMR technology provides quick and precise body composition measurement of live mice. Obes Res 9:112S
24. Blum WF, Breier BH 1994 Radioimmunoassays for IGFs and IGFBPs. Growth Regul 4:11-19
25. Inagaki N, Kuromi H, Seino S 1996 PACAP/VIP receptors in pancreatic β-cells: Their roles in insulin secretion. Ann of NY Acad Sci 805:44-53
26. Straub SG, Sharp GW 1996 Mechanisms of action of VIP and PACAP in the stimulation of insulin release. Ann NY Acad Sci 805:607-612
27. Straub SG, Sharp GW 1996 A wortmannin-sensitive signal transduction pathway is involved in the stimulation of insulin release by vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide. J Biol Chem 271:1660-1668
28. Goetzl EJ, Voice JK, Shen S, Dorsam G, Kong Y, West KM, Morrison CF, Harmar AJ 2001 Enhanced delayed-type hypersensitivity and diminished immediate-type hypersensitivity in mice lacking the inducible VPAC(2) receptor for vasoactive intestinal peptide. Proc Natl Acad Sci USA 98:13854-13859
29. Gressens P, Hill JM, Gozes I, Fridkin M, Brenneman DE 1993 Growth factor function of vasoactive intestinal peptide in whole cultured mouse embryos. Nature 362:155-158
30. Gressens P, Hill JM, Paindaveine B, Gozes I, Fridkin M, Brenneman DE 1994 Severe microcephaly induced by blockade of vasoactive intestinal peptide function in the primitive neuroepithelium of the mouse. J Clin Invest 94:2020-2027
31. Vertongen P, Solano RM, Juarranz MG, Perret J, Waelbroeck M, Robberecht P 2001 Proline residue 280 in the second extracellular loop (EC2) of the VPAC2 receptor is essential for the receptor structure. Peptides 22:1363-1370
32. Nicole P, Du K, Couvineau A, Laburthe M 1998 Site-directed mutagenesis of human vasoactive intestinal peptide receptor subtypes VIP1 and VIP2: Evidence for difference in the structure-function relationship. J Pharmacol Exp Ther 284:744-750
33. Levine JA, Eberhardt NL, Jensen MD 1999 Role of nonexercise activity thermogenesis in resistance to fat gain in humans. Science 283:212-214
34. Ravussin E, Lillioja S, Anderson TE, Christin L, Bogardus C 1986 Determinants of 24-hour energy expenditure in man. Methods and results using a respiratory chamber. J Clin Invest 78:1568-1578
35. Cagampang FR, Sheward WJ, Harmar AJ, Piggins HD, Coen CW 1998 Circadian changes in the expression of vasoactive intestinal peptide 2 receptor mRNA in the rat suprachiasmatic nuclei. Brain Res Mol Brain Res 54:108-112
36. Cagampang FR, Piggins HD, Sheward WJ, Harmar AJ, Coen CW 1998 Circadian changes in PACAP type 1 (PAC1) receptor mRNA in the rat suprachiasmatic and supraoptic nuclei. Brain Res 813:218-222
37. Hannibal J, Jamen F, Nielsen HS, Journot L, Brabet P, Fahrenkrug J 2001 Dissociation between light-induced phase shift of the circadian rhythm and clock gene expression in mice lacking the pituitary adenylate cyclase activating polypeptide type 1 receptor. J Neurosci 21:4883-4890